​

Adverum Bio (ADVM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ADVM Stock Forecast

Adverum Bio (ADVM) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $4.50, with a high of $5.00 and a low of $4.00. This represents a 6.13% increase from the last price of $4.24.

- $3 $6 $9 $12 $15 High: $5 Avg: $4.5 Low: $4 Last Closed Price: $4.24

ADVM Stock Rating

Adverum Bio stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (68.75%), 5 Hold (31.25%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 5 11 Strong Sell Sell Hold Buy Strong Buy

ADVM Price Target Upside V Benchmarks

TypeNameUpside
StockAdverum Bio6.13%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts223
Avg Price Target$4.50$4.50$6.33
Last Closing Price$4.24$4.24$4.24
Upside/Downside6.13%6.13%49.29%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25141--6
Sep, 25141--6
Aug, 25141--6
Jul, 25141--6
Jun, 25131--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025RBC Capital$4.00$4.24-5.66%-5.66%
Oct 24, 2025Joon LeeTruist Financial$5.00$4.0722.85%17.92%
Nov 05, 2024Luca IssiRBC Capital$10.00$7.7229.53%135.85%
Oct 14, 2024Francois BriseboisOppenheimer$28.00$7.81258.51%560.38%
Sep 20, 2024Graig SuvannavejhMizuho Securities$20.00$7.50166.67%371.70%
Aug 13, 2024Luca IssiRBC Capital$12.00$6.6480.72%183.02%
Nov 11, 2022Chardan Capital$2.00$0.71181.69%-52.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2025RBC CapitalSector PerformSector Performhold
Nov 05, 2024H.C. WainwrightBuyBuyhold
Oct 03, 2024OppenheimerOutperformOutperformhold
Aug 13, 2024RBC CapitalSector PerformSector Performhold
Jun 25, 2024OppenheimerOutperforminitialise
Nov 11, 2022RBC CapitalSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-14.85$-11.62$-6.62----
Avg Forecast$-14.80$-12.62$-5.01$-4.68$-4.16$-4.18$-4.21
High Forecast$-14.80$-12.22$-4.71$-3.17$-0.17$0.09$-4.21
Low Forecast$-14.80$-12.93$-5.18$-5.58$-6.55$-7.18$-4.21
Surprise %0.34%-7.92%32.14%----

Revenue Forecast

$0 $7M $14M $21M $28M $35M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.50M$3.60M$1.00M----
Avg Forecast$7.67M$3.60M$1.00M$20.20M$25.23M$32.71M$18.90M
High Forecast$7.67M$3.60M$1.00M$20.20M$25.23M$32.71M$18.90M
Low Forecast$7.67M$3.60M$1.00M$20.20M$25.23M$32.71M$18.90M
Surprise %-2.17%------

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-145.54M$-117.17M$-130.93M----
Avg Forecast$-149.22M$-126.75M$-49.83M$-44.12M$-33.88M$-35.74M$-42.45M
High Forecast$-149.22M$-123.16M$-47.46M$-32.01M$-1.71M$907.32K$-42.45M
Low Forecast$-149.22M$-130.34M$-52.19M$-56.22M$-66.04M$-72.38M$-42.45M
Surprise %-2.47%-7.56%162.77%----

ADVM Forecast FAQ

Is Adverum Bio stock a buy?

Adverum Bio stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Adverum Bio is a favorable investment for most analysts.

What is Adverum Bio's price target?

Adverum Bio's price target, set by 16 Wall Street analysts, averages $4.5 over the next 12 months. The price target range spans from $4 at the low end to $5 at the high end, suggesting a potential 6.13% change from the previous closing price of $4.24.

How does Adverum Bio stock forecast compare to its benchmarks?

Adverum Bio's stock forecast shows a 6.13% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Adverum Bio over the past three months?

  • October 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Adverum Bio’s EPS forecast?

Adverum Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.68, marking a -29.31% decrease from the reported $-6.62 in 2024. Estimates for the following years are $-4.16 in 2026, $-4.18 in 2027, and $-4.21 in 2028.

What is Adverum Bio’s revenue forecast?

Adverum Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $20.2M, reflecting a 1920.00% increase from the reported $1M in 2024. The forecast for 2026 is $25.23M, followed by $32.71M for 2027, and $18.9M for 2028.

What is Adverum Bio’s net income forecast?

Adverum Bio's net income forecast for the fiscal year ending in December 2025 stands at $-44.117M, representing a -66.30% decrease from the reported $-131M in 2024. Projections indicate $-33.877M in 2026, $-35.738M in 2027, and $-42.447M in 2028.